PMID- 16465414
OWN - NLM
STAT- MEDLINE
DCOM- 20060413
LR  - 20171116
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 15
IP  - 3
DP  - 2006 Mar
TI  - Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung 
      carcinoma cells.
PG  - 571-6
AB  - We previously demonstrated the doxorubicin-induced expression of urokinase-type 
      plasminogen activator (uPA), interleukin-8 (IL-8), monocyte chemoattractant 
      protein-1 (MCP-1) and tumor necrosis factor-alpha in human RC-K8 lymphoma cells 
      and NCI-H69 small cell lung carcinoma cells in which reactive oxygen species 
      might be involved. Amurubicin hydrochloride (AMR), a novel derivative drug of 
      doxorubicin, was recently introduced to clinical practice for treatment of lung 
      cancer in Japan. Therefore, we investigated the effects of AMR on the expression 
      of uPA and chemokines in NCI-H69 cells. AMR and its active form, amurubicinol 
      hydrochloride (AMROH), both induced the expression of uPA, IL-8 and MCP-1 in H69 
      cells in a dose-dependent manner. When the cultured supernatant obtained from 
      AMR-treated H69 cells was subcutaneously injected into rabbits, migration of a 
      significant number of eosinophils was observed around the injected site. Antigen 
      levels of eotaxin-3, a major migration-factor of eosinophils, were increased in 
      AMROH-treated cells in parallel with the mRNA levels. The induction was observed 
      below the clinically achievable concentration of AMR or AMROH. Thus, the 
      simultaneous induction of uPA, IL-8, MCP-1 and eotaxin-3 may play a role in the 
      pharmacological action of AMR through induction of the interaction between 
      proinflammatory cells and lung carcinoma cells.
FAU - Niiya, Masami
AU  - Niiya M
AD  - Department of Medicine II, Faculty of Medicine, Okayama University Medical 
      School, Okayama 700-8558, Japan. niiya7@yahoo.co.jp
FAU - Niiya, Kenji
AU  - Niiya K
FAU - Shibakura, Misako
AU  - Shibakura M
FAU - Asaumi, Noboru
AU  - Asaumi N
FAU - Yoshida, Chikamasa
AU  - Yoshida C
FAU - Tanimoto, Mitsune
AU  - Tanimoto M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Anthracyclines)
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCL26 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL26)
RN  - 0 (Chemokines, CC)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Interleukin-8)
RN  - 0 (RNA, Messenger)
RN  - 0 (amrubicinol)
RN  - 93N13LB4Z2 (amrubicin)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
SB  - IM
MH  - Animals
MH  - Anthracyclines/*pharmacology
MH  - Blotting, Northern
MH  - Carcinoma, Small Cell/genetics/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Chemokine CCL2/genetics/metabolism
MH  - Chemokine CCL26
MH  - Chemokines, CC/*genetics/metabolism
MH  - Culture Media, Conditioned/chemistry/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Eosinophils/cytology/drug effects/physiology
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Interleukin-8/genetics/metabolism
MH  - Lung Neoplasms/genetics/pathology
MH  - RNA, Messenger/genetics/metabolism
MH  - Rabbits
MH  - Urokinase-Type Plasminogen Activator/genetics/metabolism
EDAT- 2006/02/09 09:00
MHDA- 2006/04/14 09:00
CRDT- 2006/02/09 09:00
PHST- 2006/02/09 09:00 [pubmed]
PHST- 2006/04/14 09:00 [medline]
PHST- 2006/02/09 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2006 Mar;15(3):571-6.